Cyclosporin D
(Synonyms: 环孢霉素D) 目录号 : GC11866
A weak immunosuppressant
Cas No.:63775-96-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cyclosporin D is an immunosuppressive agent [1].
Cyclosporin D (CsD) is an analogue of cyclosporine A with weak immunosuppressive activity. Cyclosporin D has been used as an internal standard for the quantification of cyclosporin A. In human multidrug-resistant ovarian cancer cells, cyclosporin D significantly overcame adriamycin resistance [2]. In lymphocyte, CsD weakly inhibited PHA-, PWM-, and PMA + Ca2+-induced cell proliferation [3].
In mice, CsD inhibited edema in mouse ear and alkaline phosphatase activity in mouse skin induced by TPA by 98% and 88%, respectively. In cytosol of mouse pancreas, CsD inhibited the Ca2+/calmodulin-dependent phosphorylation of the elongation factor 2 (EF-2) and the TPA-induced increase of EF-2 [1]. Cyclosporin D was effective in inhibiting P. falciparum parasite in vitro and P. berghei malaria parasite development in vivo when administered orally [4].
References:
[1]. Gschwendt M, Kittstein W, Marks F. The weak immunosuppressant cyclosporine D as well as the immunologically inactive cyclosporine H are potent inhibitors in vivo of phorbol ester TPA-induced biological effects in mouse skin and of Ca2+/calmodulin dependent EF-2 phosphorylation in vitro. Biochem Biophys Res Commun, 1988, 150(2): 545-551.
[2]. Mizuno K, Furuhashi Y, Misawa T, et al. Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. Anticancer Res, 1992, 12(1): 21-25.
[3]. Sadeg N, Pham-Huy C, Rucay P, et al. In vitro and in vivo comparative studies on immunosuppressive properties of cyclosporines A, C, D and metabolites M1, M17 and M21. Immunopharmacol Immunotoxicol, 1993, 15(2-3): 163-177.
[4]. Uadia PO1, Ezeamuzie IC, Ladan MJ, et al. Antimalarial activity of cyclosporins A, C and D. Afr J Med Med Sci, 1994, 23(1): 47-51.
| Cas No. | 63775-96-2 | SDF | |
| 别名 | 环孢霉素D | ||
| 化学名 | (3S,6S,9S,12R,13Z,15S,16Z,18S,21S,22Z,24S,30S,31E,33R)-14,17,23,32-tetrahydroxy-6,9,18,24-tetraisobutyl-3,21,30-triisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((R,E)-2-methylhex-4-enoyl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriaconta-13,16,2 | ||
| Canonical SMILES | C/C([H])=C([H])/C[C@@](C([C@@](N1C)([H])/C(O)=N\[C@@](C(N(CC(N([C@@](/C(O)=N/[C@@](C(N([C@@](/C(O)=N/[C@@](/C(O)=N/[C@](C(N([C@@](C(N([C@@](C(N([C@@](C1=O)([H])C(C)C)C)=O)([H])CC(C)C)C)=O)([H])CC(C)C)C)=O)([H])C)([H])C)([H])CC(C)C)C)=O)([H])C(C)C)([H])CC( | ||
| 分子式 | C63H111N11O12 | 分子量 | 1214.62 |
| 溶解度 | ≥ 60.7mg/mL in DMSO with ultrasonic and warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.8233 mL | 4.1165 mL | 8.233 mL |
| 5 mM | 0.1647 mL | 0.8233 mL | 1.6466 mL |
| 10 mM | 0.0823 mL | 0.4117 mL | 0.8233 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。